Spinal Cord Stimulation Market Size Share Analysis 2022-2029

Technological advancements in the spinal cord stimulators to favor growth

Manufacturers have escalated their research programs in order to reduce the size of spinal cord stimulators. For example, Stimwave LCC's Freedom SCS system is about 5% the size of existing Implantable Pulse Generators (IPG) on the market. The spinal cord stimulation market is growing due to this, as well as improvements in impulse generation.

Stimgenics, a company based in the United States, created a new SCS waveform termed Differential Target Multiplexed (DTM) SCS. Medtronic purchased the company in January 2020. A research comparing the Differential Target Multiplexed (DTM) SCS to traditional SCSs found that the DTM SCS provided significant pain alleviation.

HF10 therapy, which has proven to be more effective than traditional spinal cord stimulation therapies, is another significant technology being used to generate the impulse. Aside from that, platforms like WaveCrest and Intellis, which can be remotely connected with smartphones and tablets to modify dose settings, are promoting SCS usage.

Medtronic is one of the key companies continually innovating to advance spinal cord stimulation therapy technologies that improve quality of life for people with chronic pain. For instance, in June 2021, Medtronic plc received U.S. Food and Drug Administration (FDA) approval for Vanta, a high performance recharge-free implantable neurostimulator (INS). It utilizes Medtronic's proprietary AdaptiveStim technology for personalized pain relief that adapts to the patient's movement or body position using a built-in accelerometer. 

The Vanta neurostimulator represents a 10% increase in longevity compared to PrimeAdvanced, Medtronic's previous generation recharge-free device. It is also 20% smaller than the PrimeAdvanced neurostimulator.

Emerging government guidelines for spinal cord stimulation to boost the market

Opioids are a type of narcotic pain reliever, which means they have a serious side effects. Patients' heavy reliance on opioid medicines to manage chronic pain has resulted in a dangerous trend of addiction.

According to the Centers for Disease Control and Prevention, approximately 168 million opioid prescriptions were written in the United States in 2018. Opioids were responsible for more than 67,000 drug overdose deaths in the United States in 2018, with prescription opioids accounting for 32% of these deaths.

As trend toward non-opioid alternative therapy, as well as an increase in demand for spinal cord stimulation devices. a result of these causes, governments in the United States, Europe, and elsewhere have boosted their efforts to reduce opiate addiction. As a result, there has been a steady 

For example, the FDA received over 200 submissions in 2018 from companies seeking a quick approval procedure for devices that can be used to treat pain instead of opioids.

The National Institute for Health and Care Excellence published guidelines and recommendations for the Senza SCS system, which uses HF10 therapy to treat neuropathic pain patients, in January 2019. Government associations' favorable recommendations are likely to support the market.

As a result, medical device companies like Medtronic, Abbott, and Boston Scientific are constantly looking for innovative ways to capitalize on this opportunity.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com